Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: A case report and review of the literature

Multidisciplinary Respiratory Medicine

Volumn 8, Issue 7, 2013, Pages

  Sakai, Yasuhiro ^a   Yamasaki, Takashi ^a   Kusakabe, Yoshito ^a   Kasai, Daisuke ^a   Kotani, Yoshikazu ^a   Nishimura, Yoshihiro ^a   Itoh, Tomoo ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Epidermal growth factor receptor; Gene mutation; Large cell neuroendocrine carcinoma; Lung cancer; Small cell carcinoma; Tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; TUMOR MARKER;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; POSITRON EMISSION TOMOGRAPHY; SYSTEMIC THERAPY;

EID: 84883437507     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-8-47     Document Type: Article

References (34)

1. Bell DW, Lynch TJ, Haserlat S.M., Harris PL, Okimoto RA, Brannigan BW, Sgroi D.C., Muir B., Riemenschneider MJ, Iacona RB, Krebs AD, Johnson D.H., Giaccone G., Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23: 8081-8092. (Pubitemid 46657411)
2. Douillard JY, Shepherd FA, Hirsh V, Mok T., Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M., Sellers MV, Watkins CL, Speake G, Armour A.A., Kim ES: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28: 744-752.
3. Eberhard DA, Johnson BE, Amler L.C., Goddard AD, Heldens SL, Herbst RS, Ince W.L., Jänne PA, Januario T., Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23: 5900-5909.
4. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A., Parikh P, Pereira JR, Ciuleanu T, Von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24: 5034-5042. (Pubitemid 46631407)
5. Wheatley-Price P., Ding K, Seymour L., Clark GM, Shepherd FA: Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26: 2350-2357.
6. Pao W, Miller V, Zakowski M., Doherty J, Politi K, Sarkaria I., Singh B, Heelan R, Rusch V., Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers," and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101: 13306-13311. (Pubitemid 39209661)
7. Mitsudomi T, Kosaka T, Endoh H., Horio Y, Hida T, Mori S., Hatooka S, Shinoda M, Takahashi T., Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23: 2513-2520. (Pubitemid 47050841)
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S., Okimoto RA, Brannigan BW, Harris PL, Haserlat S.M., Supko JG, Haluska FG, Louis DN, Christiani D.C., Settleman J., Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350: 2129-2139. (Pubitemid 38637993)
9. Paez JG, Jänne PA, Lee J.C., Tracy S., Greulich H, Gabriel S, Herman P., Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H., Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304: 1497-1500. (Pubitemid 38720929)
10. Travis WD, Brambilla E, Noguchi M., Nicholson AG, Geisinger KR, Yatabe Y, Beer D.G., Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6: 244-285.
11. Pao W, Miller VA, Politi K.A., Riely GJ, Somwar R, Zakowski MF, Kris M.G., Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
12. Zhu CQ, Da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26: 4268-4275.
13. Mao C, Qiu LX, Liao R.Y., Du FB, Ding H, Yang WC, Li J, Chen Q: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69: 272-278.
14. Cadranel J, Mauguen A, Faller M., Zalcman G, Buisine MP, Westeel V, Longchampt E., Wislez M, Coudert B, Daniel C., Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP: Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC projectpart 2). J Thorac Oncol 2012, 7: 1490-1502.
15. Boland JM, Erdogan S, Vasmatzis G., Yang P, Tillmans LS, Johnson M.R., Wang X., Peterson LM, Halling KC, Oliveira AM, Aubry M.C., Yi ES: Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009, 40: 1152-1158.
16. Yi ES, Boland JM, Maleszewski J.J., Roden AC, Oliveira AM, Aubry MC, Erickson-Johnson MR, Caron B.L., Li Y., Tang H, Stoddard S, Wampfler J., Kulig K, Yang P: Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011, 6: 459-465.
17. Araki J, Okamoto I, Suto R., Ichikawa Y, Sasaki J: Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 2005, 48: 141-144. (Pubitemid 40381011)
18. Okamoto I, Araki J, Suto R., Shimada M, Nakagawa K, Fukuoka M: EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006, 17: 1028-1029. (Pubitemid 43779001)
19. Zakowski MF, Ladanyi M, Kris M.G., Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006, 355: 213-215. (Pubitemid 44050422)
20. Morinaga R, Okamoto I, Furuta K., Kawano Y, Sekijima M, Dote K., Satou T, Nishio K, Fukuoka M., Nakagawa K: Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007, 58: 411-413. (Pubitemid 350051499)
21. Fukui T, Tsuta K, Furuta K., Watanabe S, Asamura H, Ohe Y., Maeshima AM, Shibata T, Masuda N, Matsuno Y: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 2007, 98: 1714-1719. (Pubitemid 47487906)
22. Tatematsu A, Shimizu J, Murakami Y., Horio Y, Nakamura S, Hida T., Mitsudomi T, Yatabe Y: Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14: 6092-6096.
23. Alam N, Gustafson KS, Ladanyi M, Zakowski M.F., Kapoor A., Truskinovsky AM, Dudek AZ: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 2010, 11:E1-E4.
24. Shiao TH, Chang YL, Yu C.J., Chang YC, Hsu YC, Chang SH, Shih J.Y., Yang PC: Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011, 6: 195-198.
25. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S., Turke AB, Fidias P, Bergethon K, Shaw A.T., Gettinger S., Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen J.G., Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3: 75ra26.
26. Lu HY, Sun WY, Chen B, Zhang Y.P., Cai JF, Su D, Wang Z, Zheng Y.Q., Ma SL: Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. Neoplasma 2012, 59: 100-104.
27. Lu HY, Mao WM, Cheng Q.Y., Chen B., Cai JF, Wang XJ, Wang Z, Xie FJ: Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett 2012, 3: 1288-1292.
28. Iyoda A, Travis WD, Sarkaria I.S., Jiang SX, Amano H, Sato Y, Saegusa M., Rusch VW, Satoh Y: Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med 2011, 2: 1041-1045.
29. De Pas T.M., Giovannini M, Manzotti M., Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R, Barberis M: Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol 2011, 29:e819-e822.
30. Yanagisawa S, Morikawa N, Kimura Y., Nagano Y, Murakami K, Tabata T: Large-cell neuroendocrine carcinoma with EGFR mutation: possible transformation of lung adenocarcinoma. Respirology 2012, 17: 1275-1277.
31. Balak MN, Gong Y, Riely G.J., Somwar R., Li AR, Zakowski MF, Chiang A, Yang G., Ouerfelli O, Kris MG, Ladanyi M, Miller V.A., Pao W: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12: 6494-6501. (Pubitemid 44799723)
32. Bean J, Riely GJ, Balak M, Marks J.L., Ladanyi M., Miller VA, Pao W: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14: 7519-7525.
33. Yu J, Kane S, Wu J., Benedettini E, Li D, Reeves C., Innocenti G, Wetzel R, Crosby K., Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ: Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15: 3023-3028.
34. Brevet M, Arcila M, Ladanyi M: Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12: 169-176.